Rapid assessment of in vitro expanded human regulatory T cell function
- PMID: 21781972
- DOI: 10.1016/j.jim.2011.07.001
Rapid assessment of in vitro expanded human regulatory T cell function
Abstract
Human regulatory T cells (Treg) are able to actively suppress autoreactive immune responses. Phenotypically, they are broadly characterized as CD4+, CD25+, CD127(lo/⁻) and FoxP3+. CD45RA can be used to further differentiate the population into naïve (CD45RA(+)) and induced (CD45RA⁻) Treg. The functional potential of Treg is routinely determined by assessing their ability to suppress T cell function in 3-5day proliferation assays. Since Treg are being explored for therapeutic use, a short-term functional assay could serve as a valuable tool for evaluating the potency of Treg. Therefore, an assay designed to measure Treg suppression of activation marker expression by responder T cells in 7 to 20h has been examined in this report. Using flow cytometry, expression of CD69 and CD154 on T cells, in response to stimulation with CD3/CD28 beads, was used as a measure of activation in the assay. Treg from healthy volunteers were sorted as CD4+CD25+CD127(lo/⁻)CD45RA+ cells with a BD FACSAria™ II. The highly purified Treg were then expanded in vitro and their function was assessed in short term activation marker suppression assays using autologous PBMC as responder cells. The data suggest that this short term suppression assay could be a reliable surrogate for assessing Treg functional potential.
Copyright © 2011 Elsevier B.V. All rights reserved.
Similar articles
-
CD39+Foxp3+ regulatory T Cells suppress pathogenic Th17 cells and are impaired in multiple sclerosis.J Immunol. 2009 Dec 1;183(11):7602-10. doi: 10.4049/jimmunol.0901881. Epub 2009 Nov 16. J Immunol. 2009. PMID: 19917691
-
CD4(+)CD25(+)CD127(low/-) regulatory T cells express Foxp3 and suppress effector T cell proliferation and contribute to gastric cancers progression.Clin Immunol. 2009 Apr;131(1):109-18. doi: 10.1016/j.clim.2008.11.010. Epub 2009 Jan 18. Clin Immunol. 2009. PMID: 19153062
-
A rapid diagnostic test for human regulatory T-cell function to enable regulatory T-cell therapy.Blood. 2012 Feb 23;119(8):e57-66. doi: 10.1182/blood-2011-09-380048. Epub 2012 Jan 4. Blood. 2012. PMID: 22219224 Free PMC article.
-
Suppression assays with human T regulatory cells: a technical guide.Eur J Immunol. 2012 Jan;42(1):27-34. doi: 10.1002/eji.201141651. Epub 2011 Dec 12. Eur J Immunol. 2012. PMID: 22161814 Review.
-
CD4+ T cells in inflammatory diseases: pathogenic T-helper cells and the CD69-Myl9 system.Int Immunol. 2021 Nov 25;33(12):699-704. doi: 10.1093/intimm/dxab053. Int Immunol. 2021. PMID: 34427648 Review.
Cited by
-
Short-term assays for mesenchymal stromal cell immunosuppression of T-lymphocytes.Front Immunol. 2023 Sep 26;14:1225047. doi: 10.3389/fimmu.2023.1225047. eCollection 2023. Front Immunol. 2023. PMID: 37822938 Free PMC article.
-
Differential Roles of IL-2 Signaling in Developing versus Mature Tregs.Cell Rep. 2018 Oct 30;25(5):1204-1213.e4. doi: 10.1016/j.celrep.2018.10.002. Cell Rep. 2018. PMID: 30380412 Free PMC article.
-
Isolation and analysis of tumor‑derived extracellular vesicles from head and neck squamous cell carcinoma plasma by galectin‑based glycan recognition particles.Int J Oncol. 2022 Nov;61(5):133. doi: 10.3892/ijo.2022.5423. Epub 2022 Sep 21. Int J Oncol. 2022. PMID: 36129151 Free PMC article.
-
Dominant TOM1 mutation associated with combined immunodeficiency and autoimmune disease.NPJ Genom Med. 2019 Jun 27;4:14. doi: 10.1038/s41525-019-0088-5. eCollection 2019. NPJ Genom Med. 2019. PMID: 31263572 Free PMC article.
-
Autoimmunity, hypogammaglobulinemia, lymphoproliferation, and mycobacterial disease in patients with activating mutations in STAT3.Blood. 2015 Jan 22;125(4):639-48. doi: 10.1182/blood-2014-04-570101. Epub 2014 Oct 27. Blood. 2015. PMID: 25349174 Free PMC article. Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials